Search results for "Position statement"

showing 10 items of 18 documents

Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement

2019

AbstractBackgroundNeoadjuvant treatment is increasingly one of the preferred therapeutic options for early breast cancer and may have some unique outcomes, such as identifying predictive and prognostic factors of response or increasing the knowledge of individual tumor biology.DesignA panel of experts from different specialties reviewed published clinical studies on the neoadjuvant management of breast cancer. Recommendations were made that emphasized the clinical multidisciplinary management and the investigational leverage in early breast cancer.ResultsNeoadjuvant therapy has equivalent efficacy to adjuvant therapy, and it has some additional benefits that include increasing breast conser…

0301 basic medicineOncologyPosition statementCancer Researchmedicine.medical_specialtymedicine.medical_treatmentBreast Neoplasms03 medical and health sciences0302 clinical medicineBreast cancerInternal medicineBreast CancermedicineAdjuvant therapyHumansRadical surgeryskin and connective tissue diseasesNeoadjuvant therapyEarly breast cancerChemotherapybusiness.industrymedicine.diseaseNeoadjuvant Therapy030104 developmental biologyOncology030220 oncology & carcinogenesisHormonal therapyFemalebusinessThe Oncologist
researchProduct

Acute cholecystitis during COVID-19 pandemic: a multisocietary position statement

2020

AbstractFollowing the spread of the infection from the new SARS-CoV2 coronavirus in March 2020, several surgical societies have released their recommendations to manage the implications of the COVID-19 pandemic for the daily clinical practice. The recommendations on emergency surgery have fueled a debate among surgeons on an international level.We maintain that laparoscopic cholecystectomy remains the treatment of choice for acute cholecystitis, even in the COVID-19 era. Moreover, since laparoscopic cholecystectomy is not more likely to spread the COVID-19 infection than open cholecystectomy, it must be organized in such a way as to be carried out safely even in the present situation, to gu…

Acute cholecystitis; COVID-19 pandemic; Emergency surgery; New coronavirus; Position statement; Betacoronavirus; COVID-19; Cholecystectomy; Cholecystitis Acute; Coronavirus Infections; Humans; Infection Control; Pandemics; Pneumonia Viral; SARS-CoV-2; Societies Medical; Practice Guidelines as Topicmedicine.medical_treatmentCholecystitis AcutePosition statement030230 surgery0302 clinical medicinePandemicCholecystitisInfection control030212 general & internal medicineViralSocieties Medicallcsh:Medical emergencies. Critical care. Intensive care. First aidPractice Guidelines as TopicEmergency MedicineEmergency surgeryAcute cholecystitis Emergency surgery COVID-19 pandemic New coronavirus Position statementCoronavirus InfectionsHumanPosition statementmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Pneumonia Virallcsh:SurgeryCOVID-19 pandemicNew coronaviruAcuteAcute cholecystitiacute cholecystitis; COVID-19 pandemic; emergency surgery; Nnew coronavirus; position statement; betacoronavirus; cholecystectomy; cholecystitis acute; coronavirus infections; humans; infection control; pandemics; pneumonia viral; societies medical; practice guidelines as topicNO03 medical and health sciencesBetacoronavirusEmergency surgeryMedicalmedicineAcute cholecystitisHumansCholecystectomyPandemicsAcute cholecystitis; COVID-19 pandemic; Emergency surgery; New coronavirus; Position statement; Betacoronavirus; Cholecystectomy; Cholecystitis Acute; Coronavirus Infections; Humans; Infection Control; Pandemics; Pneumonia Viral; Societies Medical; Practice Guidelines as TopicInfection ControlBetacoronaviruPandemicbusiness.industrySARS-CoV-2Coronavirus InfectionGeneral surgeryCOVID-19New coronavirusPneumonialcsh:RD1-811lcsh:RC86-88.9Acute cholecystitisSettore MED/18 - Chirurgia GeneraleInvasive surgeryCommentarySurgeryCholecystectomybusinessSocietiesWorld Journal of Emergency Surgery
researchProduct

Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23

2021

Abstract Aims  Our objective was to better understand the genetic bases of dilated cardiomyopathy (DCM), a leading cause of systolic heart failure. Methods and results  We conducted the largest genome-wide association study performed so far in DCM, with 2719 cases and 4440 controls in the discovery population. We identified and replicated two new DCM-associated loci on chromosome 3p25.1 [lead single-nucleotide polymorphism (SNP) rs62232870, P = 8.7 × 10−11 and 7.7 × 10−4 in the discovery and replication steps, respectively] and chromosome 22q11.23 (lead SNP rs7284877, P = 3.3 × 10−8 and 1.4 × 10−3 in the discovery and replication steps, respectively), while confirming two previously identif…

Cardiac & Cardiovascular SystemsCardiomyopathy Dilated/genetics[SDV]Life Sciences [q-bio]Signal Transducing/geneticsDilated cardiomyopathyGenome-wide association studyAdaptor Proteins Signal Transducing/genetics030204 cardiovascular system & hematologyTAURINE0302 clinical medicineGWASMedicinePOSITION STATEMENT1102 Cardiorespiratory Medicine and HaematologyGenetics0303 health scienceseducation.field_of_studyGenetic Predisposition to Disease/geneticsAdaptor ProteinsDilated cardiomyopathy4C-sequencingPolymorphism Single Nucleotide/geneticsGenetic risk scoreCardiology and Cardiovascular MedicineLife Sciences & BiomedicineSingle Nucleotide/geneticsCardiomyopathy DilatedCardiomyopathyPopulationLocus (genetics)Single-nucleotide polymorphismPolymorphism Single NucleotideChromosomes03 medical and health sciencesSystolic/geneticsHeart Failure Systolic/geneticsSNPAnimalsHumansGenetic Predisposition to DiseaseAllelePolymorphismeducationImputationAdaptor Proteins Signal Transducing030304 developmental biologyHeart FailureScience & Technologybusiness.industryWORKING GROUP1103 Clinical Sciencesmedicine.diseaseGenetic architectureCardiovascular System & Hematology Dilated cardiomyopathyDilated/geneticsCardiovascular System & Cardiology[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessApoptosis Regulatory ProteinsHeart Failure SystolicGenome-Wide Association Study
researchProduct

Mild cognitive decline. A position statement of the Cognitive Decline Group of the European Innovation Partnership for Active and Healthy Ageing (EIP…

2016

Introduction: Mild cognitive impairment (MCI) is a term used to describe a level of decline in cognition which is seen as an intermediate stage between normal ageing and dementia, and which many consider to be a prodromal stage of neurodegeneration that may become dementia. That is, it is perceived as a high risk level of cognitive change. The increasing burden of dementia in our society, but also our increasing understanding of its risk factors and potential interventions, require diligent management of MCI in order to find strategies that produce effective prevention of dementia. Aim: To update knowledge regarding mild cognitive impairment, and to bring together and appraise evidence abou…

GerontologyAgingConsensusRisk factors in diseases:Medicina Básica [Ciências Médicas]Psychological interventionPosition statementPrevention of dementiaGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineCognitionRisk FactorsEnvellimentTerminology as TopicIntervention (counseling)Mild cognitive declinemental disordersPrevalenceHumansMedicineDementiaPsychologyCognitive DysfunctionProspective Studies030212 general & internal medicineCognitive declineDemènciaScience & TechnologyCognitive frailtybusiness.industryFactors de risc en les malaltiesProdromal StageObstetrics and GynecologyCognitionmedicine.diseasePsicologiaCiências Médicas::Medicina BásicaCognicióDisease ProgressionTrastorns de la memòria en la vellesaDementiabusiness030217 neurology & neurosurgeryIndependent living
researchProduct

A comprehensive fracture prevention strategy in older adults : The European union geriatric medicine society (EUGMS) statement

2016

Published also in Aging Clinical and Experimental Research, Vol.28, No.4, WOS: 000379034800030 Prevention of fragility fractures in older people has become a public health priority, although the most appropriate and cost-effective strategy remains unclear. In the present statement, the Interest group on falls and fracture prevention of the European union geriatric medicine society (EUGMS), in collaboration with the International association of gerontology and geriatrics for the European region (IAGG-ER), the European union of medical specialists (EUMS), the Fragility fracture network (FFN), the International osteoporosis foundation (IOF) - European society for clinical and economic aspects …

GerontologyAgingStatement (logic)Cost effectivenessOsteoporosisPoison controlMedicine (miscellaneous)postmenopausal womenPosition statementSuicide preventionOccupational safety and healthlaw.inventionFractures Bonezoledronic acid0302 clinical medicineRandomized controlled trialBone DensitylawSecondary PreventionFallNutrition and DieteticMedicine030212 general & internal medicinerisk-factorsComputingMilieux_MISCELLANEOUSmedia_commonGeriatricsAged 80 and overHip fractureNutrition and Dietetics[SDV.MHEP.GEG] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologyosteoporotic fractures[SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologyAccidental Fallfall induced injuriesFragility fracture3. Good healthPrimary Prevention[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemrandomized controlled-trialsFracture preventionbone-mineral densityFallsHumanmedicine.drugmedicine.medical_specialtyeducationhip-fracture030209 endocrinology & metabolism[ SDV.MHEP.GEG ] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologyArticle03 medical and health sciencespharmacological-treatmentsmedia_common.cataloged_instanceHumansEuropean UnionEuropean unioncost-effectivenessAgedFragility fracturePostmenopausal womenbusiness.industryPublic healthPreventionOsteoporosimedicine.disease[SDV.AEN] Life Sciences [q-bio]/Food and NutritionZoledronic acidGeriatrics3121 General medicine internal medicine and other clinical medicineddc:618.97Physical therapyOsteoporosisAccidental FallsFalls; fragility fracture; older people; position statement; prevention; Accidental Falls; Aged; Aged 80 and over; European Union; Fractures Bone; Geriatrics; Humans; Osteoporosis; Medicine (miscellaneous); Nutrition and Dietetics; Geriatrics and GerontologyOlder peopleGeriatrics and GerontologybusinessOlder people[SDV.AEN]Life Sciences [q-bio]/Food and NutritionGerontologyGeriatric
researchProduct

Management of depressive symptoms in peri- and postmenopausal women: EMAS position statement.

2019

Introduction: Globally, the total number of people with depression exceeds 300 million, and the incidence rate is 70 % greater in women. The perimenopause is considered to be a time of increased risk for the development of depressive symptoms and major depressive episodes. Aim: The aim of this position statement is to provide a comprehensive model of care for the management of depressive symptoms in perimenopausal and early menopausal women, including diagnosis, treatment and follow-up. The model integrates the care provided by all those involved in the management of mild or moderate depression in midlife women. Materials and methods: Literature review and consensus of expert opinion. Summa…

Position statementAdultComplementary Therapiesmedicine.medical_specialtyPeriMenopausal Hormone TherapyGeneral Biochemistry Genetics and Molecular BiologyEMAS03 medical and health sciences0302 clinical medicinemedicineHumans030212 general & internal medicineModel of CarePsychiatryEarly MenopauseLife StyleDepressive symptomsDepression (differential diagnoses)Societies MedicalAgedDepressive Disorder Major030219 obstetrics & reproductive medicinePostmenopausal womenVasomotorbusiness.industryDepressionObstetrics and GynecologyMenopausal TransitionMiddle AgedAntidepressive AgentsHormones3. Good healthPerimenopauseEuropePostmenopauseTreatment OutcomePractice Guidelines as TopicFemaleMenopausal hormone therapyMenopausebusinessPsychosocialMaturitas
researchProduct

Prevention, diagnosis, and treatment of obesity. 2016 position statement of the Spanish Society for the Study of Obesity.

2017

Position statementAdultMaleSpanish Society for the Study of ObesityPALABRASPediatricsmedicine.medical_specialtyPediatric ObesityMEDLINEBariatric SurgeryComorbidity030204 cardiovascular system & hematologyModels BiologicalComorbidities03 medical and health sciencesDisease susceptibility0302 clinical medicineSleep Apnea SyndromesDiabetes mellitusDiagnosismedicinePrevalenceHumans030212 general & internal medicineObesityChildExerciseAdiposityDyslipidemiasInflammationbusiness.industryPreventionmedicine.diseaseObesityComorbidityDietTreatmentDiabetes Mellitus Type 2Cardiovascular DiseasesSpainBody CompositionFemaleAnti-Obesity AgentsDisease SusceptibilitybusinessEnergy IntakeEndocrinologia, diabetes y nutricion
researchProduct

Spanish Menopause Society position statement: Use of denosumab in postmenopausal women

2014

Denosumab is a new drug developed for the treatment of osteoporosis. Moreover, increasing evidences link denosumab with benefits in cancer, an area of interest for those in charge of the postmenopausal health. Denosumab has shown efficacy in the control of bone loss associated with hypogonadic states created by chemotherapy in breast and other cancers. Moreover, some studies reveal efficacy in reducing the progression of metastases. A panel of experts from the Spanish Menopause Society has met to develop usage recommendations based on the best available evidence.

Position statementOncologymedicine.medical_specialtyInjections SubcutaneousOsteoporosisBone NeoplasmsBreast NeoplasmsGeneral Biochemistry Genetics and Molecular BiologyFractures BoneBreast cancerBone DensityInternal medicinemedicineHumansOsteoporosis PostmenopausalPostmenopausal womenBone Density Conservation Agentsbusiness.industryObstetrics and GynecologyCancerArea of interestmedicine.diseasePostmenopauseMenopauseDenosumabDisease ProgressionPhysical therapyFemaleBone RemodelingDenosumabSafetybusinessmedicine.drugMaturitas
researchProduct

Facial masks in children: the position statement of the Italian pediatric society

2020

AbstractFacial masks may be one of the most cost-effective strategies to prevent the diffusion of COVID 19 infection. Nevertheless, fake news are spreading, alerting parents on dangerous side effects in children, such as hypercapnia, hypoxia, gut dysbiosis and immune system weakness. Aim of the Italian Pediatric Society statement is to face misconception towards the use of face masks and to spread scientific trustable information.

Position statementWeakness2019-20 coronavirus outbreakmedicine.medical_specialtyConsensusCoronavirus disease 2019 (COVID-19)Pneumonia ViralFake newBetacoronavirus03 medical and health sciences0302 clinical medicineFacial mask030225 pediatricsDisease Transmission InfectiousmedicineHumansInfection control030212 general & internal medicinePsychiatryChildPandemicsChildrenCOVIDInfection ControlMaskPandemicBetacoronaviruSARS-CoV-2business.industryCoronavirus InfectionMaskslcsh:RJ1-570COVID-19lcsh:PediatricsEquipment DesignSettore MED/38Face masksDisease Transmission InfectiouFake newsCommentaryGut dysbiosisFake newsmedicine.symptomCoronavirus InfectionsbusinessHumanItalian Journal of Pediatrics
researchProduct

Kids Save Lives – ERC position statement on school children education in CPR.

2016

Sudden out-of-hospital cardiac arrest (OHCA) with unsuccessful cardiopulmonary resuscitation (CPR) is the third leading cause of death in industrialised nations.1 After OHCA, the overall survival rates are 2–10%.2–4 In Europe and in the US together, 700,000 people die of OHCA every year. The same applies to other industrialised regions of the world. Many of these lives could be saved if more lay people provided immediate CPR.2 Emergency medical services (EMS) response times can be several (6–12) minutes or even longer.

Position statementbusiness.industrymedicine.medical_treatment030208 emergency & critical care medicine030204 cardiovascular system & hematologyEmergency Nursingmedicine.disease3. Good health03 medical and health sciences0302 clinical medicineEmergency MedicineOverall survivalmedicineEmergency medical servicesCardiopulmonary resuscitationMedical emergencyCardiology and Cardiovascular MedicinebusinessCause of deathResuscitation
researchProduct